Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Saturday, October 1, 2011

Expert comment on the new paper connecting TMA level with PYROXD2 enzyme

The new paper about trimethylamine and enzyme PYROXD2 has been a lot of new information to take in. How significant the paper will be to people with genetic TMAU due to FMO3 deficiency is yet to unfold.

 An expert in TMAU/FMO research, Dr Ian Phillips of Queen Mary University of London, has kindly given us his first observations of the new paper, which is posted below :

Comment by Dr Ian Phillips
Queen Mary University of London

The paper describes a so-called metabolite quantitative trait locus (mQTL) study. Basically, the researchers looked for associations between the concentrations of various metabolites (small molecules involved in biochemical processes) in urine and plasma and genetic variation (single-nucleotide polymorphisms (SNPs)) from across the entire human genome. They found that ‘high’ concentrations of trimethylamine (TMA) in urine were associated with a T version of a T/C SNP (rs7072216) present in the PYROXD2 gene, which encodes a probable pyridine nucleotide-disulphide oxidoreductase. The gene is on chromosome 10, whereas the FMO3 gene is on chromosome 1.

The results suggest that common variants of the PYROXD2 gene or of a gene that is close to it can affect the amount of TMA excreted in urine. However, the authors state that the 'high' urinary concentrations of TMA associated with TT homozygotes are within the range found in individuals unaffected by primary genetic TMAuria, which is caused by defects in FMO3. Also, the T version of the SNP is present in Europeans at high frequency (70%), which indicates that a relatively high proportion of individuals will be homozygous for the T version of the SNP. Therefore, the SNP is not relevant to primary genetic TMAuria. However, if a person with primary TMAuria is homozygous for the T version of the SNP, the condition might be worse. In addition, it is possible that mild or transient forms of TMAuria, involving common polymorphisms of FMO3, would be exacerbated in people who are homozygous for the T version of the SNP.


Post a Comment